[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Children's Hospital of Chongqing Medical University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":230},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,45,76,101,128,155,183,208],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100531531","vitamin-d-treat-to-target-strategy-for-children-with-overactive-bladder-wet-100531531",false,"NCT06201013","Vitamin D Treat-to-Target Strategy for Children With Overactive Bladder-Wet","Efficacy, Neural Repair Mechanism, and Health Economics of a Multimodal Treat-to-Target Strategy Incorporating Vitamin D for Pediatric Overactive Bladder-Wet: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Children older than or equal to 5 years of age with a diagnosis of wet OAB (the diagnosis followed the latest guidelines of ICCS) attending the outpatient clinic of the Department of Urology of the Affiliated Children's Hospital of Chongqing Medical University,\n* children with serum vitamin D levels below 35 ng\u002Fml as indicated by the tests conducted by the hospital\n* children whose guardians have given their informed consent, are able to ensure compliance and have signed a paper-based informed consent form.\n\nExclusion Criteria:\n\n* Those with urinary malformations or serious diseases (e.g., hypospadias, cryptorchidism, posterior urethral valvulae, vesicoureteral reflux, neurogenic bladder, urinary tumors, urinary stones, bladder and urethral injuries, etc.)\n* Those with neurological disorders (e.g., epilepsy, spinal cord injuries, spinal dysplasia, spinal embolism syndrome, multiple sclerosis, and autism spectrum disorders, etc.)\n* People with serious heart disease, abnormal liver and kidney function, lung disease, bone deformity, serious digestive tract disease, genetic metabolic disease\n* People with history of gastrointestinal surgery and urological surgery\n* People with dry stools and long-term constipation\n* People who are taking anticonvulsant and antiepileptic drugs, hormones, and anti-tuberculosis drugs\n* People with history of hypercalcemia, hyperphosphatemia with renal rickets\n* People who have had unexplained hematuria and hematuria with renal rickets within the last year\n* People who have been suffering from severe heart disease or chronic diabetes.\n* participation in other clinical studies at the time of consultation or during the follow-up period of other clinical studies\n* unwillingness to participate in this study","ALL","5 Years","18 Years",{"count":20,"type":21},180,"ESTIMATED","INTERVENTIONAL",[24],"NA","The purpose of this clinical trial is to investigate whether adding high-dose vitamin D (2,400 IU daily) to standard medical treatment (solifenacin combined with behavioral therapy) is more effective than standard treatment alone for children with overactive bladder-wet (OAB-wet).\n\nOAB-wet causes sudden urinary urges and frequent daytime or incontinence, which significantly impacts a child's quality of life and increases the family's caregiving burden. While solifenacin is a standard medication used to calm the bladder, many children do not achieve complete dryness. This study introduces the \"Treat-to-Target\" (T2T) approach, where clinicians and families set personalized \"functional goals\" (such as zero leakage) and monitor progress closely to adjust care.\n\nThe study aims to answer the following questions:\n\nDoes adding vitamin D help more children achieve their goal of \"zero leakage\" compared to standard treatment? Does vitamin D help repair bladder-related nerves, as measured by a specific marker in the urine? Does this combined approach reduce the family's expenses (like laundry costs and diaper use) and improve the child's self-esteem?\n\nParticipants will be randomly assigned to one of two groups for 12 weeks:\n\nIntervention Group: Standard care (solifenacin + behavioral therapy) plus daily vitamin D (2,400 IU).\n\nControl Group: Standard care (solifenacin + behavioral therapy) alone. Researchers will evaluate symptoms, vitamin D levels, and nerve repair markers at 6 and 12 weeks to determine the best treatment strategy for these children.",[27,28,29],"Urinary Bladder, Overactive","Overactive Bladder","Urinary Incontinence, Urge",[27,29,31],"Vitamin D","RECRUITING","2026-04-14",{"date":35,"type":36},"2026-04-17","ACTUAL",{"date":38,"type":21},"2026-04-20",{"date":40,"type":21},"2027-04-15",{"name":42,"class":43},"Children's Hospital of Chongqing Medical University","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":63,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},"100509320","the-effect-of-high-caloric-oral-nutritional-supplements-on-growth-and-development-of-malnourished-children-100509320","NCT05911893","the Effect of High Caloric Oral Nutritional Supplements on Growth and Development of Malnourished Children","EHCONSGDMC","Inclusion Criteria:\n\n* Aged 1-3 years\n* BMI for Age Z-score\\\u003C-2\n* Height-for-age z score\\\u003C-2\n* Total daily energy intake\\\u003C75% of recommended nutrient intake\n* The child's guardian is willing to participate in this study and sign an informed consent form.\n\nExclusion Criteria:\n\n* Chronic or severe infectious disease (e.g., chronic hepatitis, HIV or tuberculosis infection)\n* Certain congenital or genetic diseases affecting physical growth and development (congenital heart disease, Down's syndrome, infantile anorexia nervosa, etc.), malignancies and use of drugs (diuretics, appetite stimulants, steroids and growth hormones, etc.)\n* Severe gastrointestinal disorders (e.g., celiac disease, short bowel syndrome, inflammatory bowel disease, etc.)\n* Acute and chronic respiratory\u002Fdigestive tract infections within 2 weeks prior to enrollment\n* Allergy or contraindication to any of the ingredients in the high-energy total nutrition formula used in this study\n* Have used high-energy enteral nutrition preparations for the last 3 months","1 Year","3 Years",{"count":55,"type":21},200,[24],"The goal of this clinical trial is to investigate the effect of high caloric oral nutritional supplements on body proportion, weight, linear growth pattern, neuropsychological development level and related health aspects (gut health, immune function, quality of life, etc.) in participants aged 1 to 3 years who are malnourished (underweight and wasting),as well as to evaluate the safety of applying high caloric oral nutritional supplements. Participants will receive nutritional education and daily high caloric oral nutritional supplements(experimental group),or will receive nutritional education and dietary instruction(control group).This study may provide data to support the development of clinical intervention strategies for malnourished Chinese children.",[59,60,61,62],"Malnutrition, Child","Malnourishment","Nutritional Deficiency","Undernutrition",[64,65,66],"Oral Nutritional Supplements","Physique Growth","Neuropsychological Development","2026-03-16",{"date":69,"type":36},"2026-03-18",{"date":71,"type":36},"2024-06-17",{"date":73,"type":21},"2026-03-10",{"name":42,"class":43},13,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":82,"sex":16,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":87,"studyType":88,"phases":4,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":98,"leadSponsor":100,"locationsCount":4},"100629296","research-on-speech-development-trajectories-and-predictive-models-in-children-with-autism-spectrum-disorder-100629296","NCT07472829","Research on Speech Development Trajectories and Predictive Models in Children With Autism Spectrum Disorder","Inclusion Criteria:\n\n* Diagnosed as typically developing children by two or more associate chief physicians.\n* Gender- and age-matched to the ASD group.\n* Participants whose native language is Chinese.\n\nExclusion Criteria:\n\n* Participants not meeting the age requirement.\n* Presence of orofacial motor and swallowing dysfunction.\n* Hearing impairment.\n* Participants whose native language isn't Chinese.\n* Neurological disorders (such as encephalitis or seizures) and comorbid psychiatric disorders.",true,"18 Months","60 Months",{"count":86,"type":21},120,"3 Months","OBSERVATIONAL","Recent studies indicate that children with ASD have a significantly higher risk of co-occurring speech sound disorders than typically developing children. Early atypical speech development may be a critical yet overlooked bottleneck hindering their language improvement. Given the unique phonetic features of Mandarin, it is essential to investigate speech development in Mandarin-speaking children with ASD. This study aims to construct developmental trajectories and establish early identification and prognosis prediction models for this population.",[91,92],"Speech","Autism Spectrum Disorder (ASD)","NOT_YET_RECRUITING","2026-03-14",{"date":96,"type":36},"2026-03-17",{"date":73,"type":21},{"date":99,"type":21},"2027-12-31",{"name":42,"class":43},{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":82,"sex":16,"minAge":109,"maxAge":110,"enrollmentInfo":111,"targetDuration":4,"studyType":88,"phases":4,"briefSummary":113,"conditions":114,"keywords":116,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":44},"100474776","normal-reference-range-for-neonatal-echocardiography-100474776","NCT05462301","Normal Reference Range for Neonatal Echocardiography","Normal Reference Range for Neonatal Echocardiography: a Multi-center, Prospective Study","NORRNE","Inclusion Criteria:\n\n* Outpatient or inpatient neonate\n* Gestational age \\> 30weeks and birthweight \\> 1250 grams\n* Appropriate for gestational age\n* Without perinatal asphyxia\n* Without skin lesion on the left chest wall\n* with family informed consent for neonatal echocardiography\n\nExclusion Criteria:\n\n* specialist cardiac ultrasound suggests congenital heart disease;\n* PDA with hemodynamic abnormalities, defined as: PDA \\> 1.5 mm (left-to-right shunt) and left atrial diameter\u002Faortic root \\> 1.5 or the need for the use of inotropes;\n* invasive mechanical ventilation therapy,\n* non-invasive mechanical ventilation with FiO2 \\>0.3\n* major anomalies\n* blood culture-proven neonatal sepsis\n* persistent pulmonary hypertension\n* renal failure\n* necrotizing enterocolitis ≥ stage II\n* post surgery\n* Maternal history of severe anemia, or prenatal massive bleeding","1 Day","28 Days",{"count":112,"type":21},1500,"Echocardiography is the main method of bedside examination of neonatal cardiac morphology, which can timely diagnose congenital heart disease and quantitatively assess its severity, but the diagnosis and evaluation process depends on the normal range of neonatal echocardiography.At present, there have been normal reference standards for echocardiography in children and adults at home and abroad, but there is no uniform standard for echocardiographic parameters in newborns, especially premature infants.This study intends to carry out a national multicenter, prospective, observational study to establish the reference range of echocardiography at different time periods after birth in newborns, and stratified according to gestational age, birth weight and gender, to conduct a more accurate hemodynamic assessment of clinically critically ill newborns and guide the treatment of critically ill newborns in real time.",[115],"Echocardiography",[117,118,119],"Neonatal Echocardiogram","Reference Ranges","Preterm Infants","2024-07-13",{"date":122,"type":36},"2024-07-16",{"date":124,"type":36},"2022-11-15",{"date":126,"type":21},"2024-12-30",{"name":42,"class":43},{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":135,"enrollmentInfo":136,"targetDuration":4,"studyType":22,"phases":138,"briefSummary":140,"conditions":141,"keywords":143,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":44},"100504106","phase-2-efficacy-and-safety-of-rituximab-versus-mycophenolate-mofetil-in-children-with-steroid-dependent-nephrotic-syndrome-100504106","NCT05843968","Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil in Children With Steroid-dependent Nephrotic Syndrome","Rituximab Versus Mycophenolate Mofetil in Children With Steriod-dependent Nephrotic Syndrome: A Single-center, Randomized Controlled Trial","Inclusion Criteria:\n\n* Children with a definite diagnosis of SDNS are included in the study during relapse treatment.\n* Age 3-16 years.\n* Steroid dependent dose≤0.3mg\u002Fkg\u002Fday.\n* Cumulative steroid use for ≥6 months.\n* Ability to swallow tablet.\n* Guardians understand the characteristics and personal consequences of clinical trial.\n* Guardians willing to give informed written consent.\n\nExclusion Criteria:\n\n* Diagnosis of secondary NS, such as secondary to lupus nephritis, hepatitis B-related nephritis, purpura nephritis, etc.\n* Anti-neutrophil cytoplasmic antibodies(ANCA) positive or complement C3 level decreased.\n* Diagnosis of hereditary nephrotic syndrome.\n* Full dose of prednisone (2mg\u002Fkg\u002Fday, maximum 60mg) are used for 14 days after relapse and urine protein don't turn negative.\n* Estimated glomerular filtration rate (eGFR) \\\u003C90mL\u002Fmin per 1.73m\\^2 at study entry.\n* Those who with a known allergy to Mycophenolate Mofetil and their excipients or to Rituximab and its excipients.\n* Those who refuse to participate in the trial.\n* Those who participate other clinical trials.\n* Those who with positive HBV serological markers (HBsAg or\u002Fand HBeAg or\u002Fand HBcAb), HCV positive patients or patients with abnormal liver function (ALT,AST,or bilirubin\\>2 or more times the upper limit of the normal range and persistently elevated for 2 weeks).\n* Severe leukopenia (white blood cells\\\u003C3.0×10\\^9), severe anemia (hemoglobin\\\u003C90g\u002Fl), and thrombocytopenia (platelets\\\u003C100×10\\^9) at study entry.\n* History of pancreatitis or definite gastrointestinal ulcers and\u002For gastrointestinal bleeding within 6 months.\n* Those who with congenital or acquired immune deficiency, or with active tuberculosis, active CMV and other infections.\n* Those who with other serious physical or mental illnesses.\n* History of malignant tumor within 5 years.\n* Those who with congenital heart disease, arrhythmia, heart failure and other serious cardiovascular diseases.\n* Those who with serious infections requiring intravenous antibiotics.","16 Years",{"count":137,"type":21},46,[139],"PHASE2","The goal of this clinical trial is to evaluate the efficacy and safety of rituximab(RTX) and mycophenolate mofetile(MMF) in the treatment of children with low-dose steroid-dependent nephrotic syndrome(SDNS).",[142],"Nephrotic Syndrome in Children",[144,145,146],"Nephrotic Syndrome","Rituximab","Mycophenolate Mofetil","2024-04-18",{"date":149,"type":36},"2024-04-19",{"date":151,"type":36},"2023-01-29",{"date":153,"type":21},"2026-07-01",{"name":42,"class":43},{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":82,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":162,"targetDuration":163,"studyType":88,"phases":4,"briefSummary":164,"conditions":165,"keywords":171,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":44},"100517862","hepatitis-b-vaccination-after-neonatal-surgery-100517862","NCT06023056","Hepatitis B Vaccination After Neonatal Surgery","Influence of Delayed Vaccination of Hepatitis B Vaccine on Vaccination Safety and Immune Response of Newborns After Gastrointestinal Surgery","Inclusion Criteria:\n\n1\\. Term neonates; 2. Underwent staged gastrointestinal surgery; 3. HBsAg-; 4. No immune system disease; 5.no serious defect of heart, brain, liver, kidney and other organs.\n\nExclusion Criteria:\n\n1\\. Premature; 2. HBsAg+; 3. Having immune system diseases; 4. Having serious defect of heart, brain, liver, kidney and other organs; 5. Lost patients.",{"count":20,"type":21},"2 Years","At present, whether the hepatitis B vaccine (HBV) can be vaccinated on time after neonatal surgery has become a common problem for children's families, neonatal surgeons, and vaccination departments, but there are few relevant studies at home and abroad, and there is no corresponding guide or consensus. In the early stage, our research team investigated the vaccination plans of the vaccination units in the main urban areas of Chongqing for such children through telephone follow-up, and found that the practices of each unit were different, all based on their own experience, and there was no clear evidence to support the vaccination or should not be vaccinated, which may cause some children to miss the best vaccination time or increase the risk of vaccination. The center is a relatively large neonatal surgery center in southwest China. The diagnosis and treatment of neonatal digestive tract malformations is at the leading level in China. It can carry out various neonatal operations such as neonatal necrotizing enterocolitis, congenital anorectal malformations, and congenital megacolon. On average, it carries out more than 30 third and fourth grade neonatal gastrointestinal operations every month. It has accumulated a lot of experience in the follow-up of newborns, There is a large amount of clinical data support for children who need to be vaccinated after surgery, so it is planned to follow up the second and third doses of hepatitis B vaccine and whether there are adverse reactions related to vaccination for children who need to be vaccinated after gastrointestinal surgery in the neonatal period, and at the same time check the production of HBsAb after vaccination, The immune response and adverse reactions of hepatitis B vaccine at different time points after surgery were studied to increase clinical evidence for the determination of hepatitis B vaccine vaccination program for newborns after surgery.",[166,167,168,169,170],"Vaccination Reaction","Hepatitis B Virus Infection","Digestive System Disorders of Fetus and Newborn","Blood Transfusion Complication","Hepatitis B Vaccine Adverse Reaction",[172,170,173,174],"Hepatitis B Vaccination Reaction","Neonatal surgery","Gastrointestinal Surgery","2023-09-07",{"date":177,"type":36},"2023-09-11",{"date":179,"type":36},"2022-11-01",{"date":181,"type":21},"2030-11-01",{"name":42,"class":43},{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":187,"acronym":4,"eligibilityCriteria":188,"healthyVolunteers":82,"sex":16,"minAge":189,"maxAge":190,"enrollmentInfo":191,"targetDuration":4,"studyType":88,"phases":4,"briefSummary":193,"conditions":194,"keywords":196,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":44},"100498295","the-role-of-biomarkers-in-the-occurrence-and-development-of-asthma-100498295","NCT05768399","The Role of Biomarkers in the Occurrence and Development of Asthma","Inclusion Criteria:\n\n* In line with the diagnostic criteria in the Guidelines for the Diagnosis and Prevention of Bronchial Asthma in Children (2016 Edition)\n* Age: 4-12 years old for new diagnosis or recurrent episodes\n* Typical clinical manifestations and complete clinical data\n* Family members or guardians of children with informed research and signed consent\n* All healthy control subjects had no history of lung disease, allergic rhinitis or any other atopic disease\n\nExclusion Criteria:\n\n* Suffering from other respiratory diseases (such as bronchiectasis, allergic rhinitis, respiratory failure, tuberculosis, obstructive airway disease) or other inflammatory diseases.\n* Abnormal development of congenital airway and lung tissue\n* History of immunosuppressant or glucocorticoid use in the first 4 weeks\n* Suffering from other endocrine system and immune system diseases\n* Incomplete clinical data or examinations.","4 Years","12 Years",{"count":192,"type":21},2,"To study the expression level of biomarkers such as GITRL in peripheral blood of children with asthma and analyze their correlation with the severity of asthma. To study the predictive value of biomarkers level for the occurrence and development of asthma. And to provide supplementary detection means and predictive indicators for the diagnosis of asthma and the severity of asthma.",[195],"Asthma in Children",[197,198,199],"asthma","children","biomarkers","2023-07-05",{"date":202,"type":36},"2023-07-07",{"date":204,"type":36},"2023-07-04",{"date":206,"type":21},"2029-12-31",{"name":42,"class":43},{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":42,"acronym":4,"eligibilityCriteria":213,"healthyVolunteers":82,"sex":16,"minAge":214,"maxAge":18,"enrollmentInfo":215,"targetDuration":17,"studyType":88,"phases":4,"briefSummary":217,"conditions":218,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":44},"100399191","design-and-implementation-of-the-pediatric-liver-transplantation-biobank-100399191","NCT04477967","Design and Implementation of the Pediatric Liver Transplantation Biobank","Inclusion Criteria:\n\n1. Children diagnosed with end-stage liver disease.\n2. Liver transplantation in our hospital.\n3. informed patient consent.\n4. long-term follow-up in our hospital.\n\nExclusion Criteria:\n\nNo fixed contact information, difficult to follow up the patients.","1 Month",{"count":216,"type":21},500,"The purpose of the pediatric liver transplant biobank is to systematically collect clinical specimens from pediatric end-stage liver disease. It is expected to contribute to the research and development of paediatric end-stage liver disease in the future.",[219,220,221],"Liver Diseases","Liver Transplant; Complications","Pediatric ALL","2020-07-15",{"date":224,"type":36},"2020-07-20",{"date":226,"type":36},"2018-10-01",{"date":228,"type":21},"2028-07-01",{"name":42,"class":43},""]